实体器官移植受者接受霉酚酸类药物TDM的意愿调查

刘爽; 陈鸿圣; 郭琦; 程吟楚; 赵荣生; 侯小飞

doi:10.6039/j.issn.1001-0408.2024.01.16

您当前的位置：

首页 >

文章列表页 >

实体器官移植受者接受霉酚酸类药物TDM的意愿调查

药师与药学服务 | 更新时间：2024-01-11

- 实体器官移植受者接受霉酚酸类药物TDM的意愿调查
- Investigation of patients’ preferences regarding therapeutic drug monitoring of mycophenolic acid in solid organ transplantation
- 中国药房 2024年35卷第1期页码：90-94
- 作者机构：
  
  1.北京大学第三医院药剂科，北京　100191
  2.北京大学医学部药品评价中心，北京　100191
  3.北京大学药学院药事管理与临床药学系，北京　100191
  4.北京大学第三医院泌尿外科，北京　100191
- 作者简介：
  
  药师，硕士。研究方向：循证药学、治疗药物监测。 E-mail：liushuang@bjmu.edu.cn
  主任医师，博士生导师，博士。研究方向：同种异体或亲属肾脏、胰肾联合、血管等移植及常见泌尿系疾病。E-mail：houxf12@163.com
- 基金信息：
  
  国家自然科学基金资助项目(72074005)
- DOI：10.6039/j.issn.1001-0408.2024.01.16
  中图分类号： R969.3;S857.13+4
- 纸质出版日期：2024-01-15，
  
  收稿日期：2023-07-14，
  
  修回日期：2023-12-12，
扫描看全文
刘爽,陈鸿圣,郭琦等.实体器官移植受者接受霉酚酸类药物TDM的意愿调查 ^Δ[J].中国药房,2024,35(01):90-94.

LIU Shuang,CHEN Hongsheng,GUO Qi,et al.Investigation of patients’ preferences regarding therapeutic drug monitoring of mycophenolic acid in solid organ transplantation[J].ZHONGGUO YAOFANG,2024,35(01):90-94.
刘爽,陈鸿圣,郭琦等.实体器官移植受者接受霉酚酸类药物TDM的意愿调查 ^Δ[J].中国药房,2024,35(01):90-94. DOI： 10.6039/j.issn.1001-0408.2024.01.16.

LIU Shuang,CHEN Hongsheng,GUO Qi,et al.Investigation of patients’ preferences regarding therapeutic drug monitoring of mycophenolic acid in solid organ transplantation[J].ZHONGGUO YAOFANG,2024,35(01):90-94. DOI： 10.6039/j.issn.1001-0408.2024.01.16.

摘要

目的

调查实体器官移植受者接受霉酚酸类（MPA）药物治疗药物监测（TDM）的意愿，并探究相关影响因素，为相关指南推荐意见形成及临床决策优化提供参考。

方法

采用横断面研究设计法，设计MPA TDM患者意愿调查问卷，选取2022年4月14日至2022年6月27日在北京市两家三级甲等综合医院接受MPA类药物治疗的实体器官移植受者进行调研。采用Likert 5级评分法对患者接受MPA TDM的意愿进行评分，采用Pearson相关分析和二元Logistic回归分析患者接受MPA TDM的意愿影响因素及其相关性，采用非参数检验和

检验对影响患者意愿决策的因素进行排序及一致性分析。

结果

共收集到有效问卷140份，有效回收率为77.35%。140例患者接受MPA TDM的平均意愿得分为（4.01±0.65）分，表明总体意愿值较高；有116例（82.86%）患者表示愿意或非常愿意接受MPA TDM；既往接受过TDM与未接受过TDM患者的意愿得分差异有统计学意义[（4.30±0.53）分 vs. （3.80±0.65）分，

＜0.001]。患者对MPA TDM的了解程度、重视程度与接受意愿呈显著正相关（

＜0.001）。患者决策影响因素排序具有统计学上的一致性（

＜0.001），影响程度由大到小分别为治疗有效性、安全性、舒适程度、经济性及时间成本。

结论

实体器官移植受者对MPA TDM的接受意愿较高，MPA TDM既往就诊经历和对MPA TDM的了解、重视程度为影响患者意愿的主要因素。

Abstract

OBJECTIVE

To investigate the preferences of patients who underwent solid organ transplantation regarding therapeutic drug monitoring （TDM） of mycophenolic acid （MPA） and explore the factors influencing patients’ decision-making process， so as to provide support for the development of individualized medication guidelines for MPA and improvement of clinical decision-making.

METHODS

The cross-sectional study was used to design the questionnaire on the patients’ preferences to accept MPA TDM， and involved patients who underwent solid organ transplantation and received MPA treatment at two tertiary hospitals in Beijing from April 14， 2022， to June 27， 2022. The Likert 5-level scoring method was used to score the patients’ preferences to accept MPA TDM， the influencing factors and their correlation of the patients’ preferences to accept MPA TDM were analyzed by Pearson correlation analysis and binary Logistic regression analysis， and the nonparametric test and chi-square test were used to rank and analyze the consistency of the factors affecting patients’ preference decision.

RESULTS

A total of 140 questionnaires were collected， and the effective recovery rate was 77.35%. The average preference score of 140 patients to receive MPA TDM was （4.01±0.65）， and the overall preference value was high. There were 116 （82.86%） patients agreed or strongly agreed with MPA TDM. Significant differences were observed in preference scores between patients who had previously undergone MPA TDM and those who had never undergone it [（4.30±0.53） scores vs. （3.80±0.65） scores，

＜0.001]. Additionally， patients’ preference scores were significantly influenced by their understanding level and attention level （

＜0.001）. The ranking of factors contributing to decision-making exhibited consistency （

＜0.001）. The factors were ranked in descending order of clinical efficacy， safety， comfortability， economy and time cost.

CONCLUSIONS

The patients who underwent solid organ transplantation hold high preferences towards MPA TDM. The primary factors influencing their decisions are their prior experience， understanding level， and attention level.

关键词

霉酚酸类药物治疗药物监测患者意愿实体器官移植问卷调查

Keywords

therapeutic drug monitoringpatient’s preferencessolid organ transplantationquestionnaire survey

references

NELSON J，ALVEY N，BOWMAN L，et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation：endorsed by the American College of Clinical Pharmacy，American Society of Transplantation，and the International Society for Heart and Lung Transplantation[J]. Pharmacotherapy，2022，42（8）：599-633.

LENTINE K L，SMITH J M，MILLER J M，et al. OPTN/SRTR 2021 annual data report：kidney[J]. Am J Transplant，2023，23（2 Suppl 1）：S21-S120.

COLVIN M M，SMITH J M，AHN Y S，et al. OPTN/SRTR 2021 annual data report：heart[J]. Am J Transplant，2023，23（2 Suppl 1）：S300-S378.

KWONG A J，EBEL N H，KIM W R，et al. OPTN/SRTR 2021 annual data report：liver[J]. Am J Transplant，2023，23（2 Suppl 1）：S178-S263.

VALAPOUR M，LEHR C J，SCHLADT D P，et al. OPTN/SRTR 2021 annual data report：lung[J]. Am J Transplant，2023，23（2 Suppl 1）：S379-S442.

BERGAN S，BRUNET M，HESSELINK D A，et al. Personalized therapy for mycophenolate：consensus report by the International Association of Therapeutic Drug Monito- ring and Clinical Toxicology[J]. Ther Drug Monit，2021，43（2）：150-200.

DJULBEGOVIC B，GUYATT G H. Progress in evidence-based medicine：a quarter century on[J]. Lancet，2017，390（10092）：415-423.

Institute of Medicine （US） Committee on Standards for Developing Trustworthy Clinical Practice Guidelines，GRAHAM R，MANCHER M，et al. Clinical practice guidelines we can trust[M]. Washington （DC）：National Academies Press （US），2011：1-290.

BAI F，LING J，ESOIMEME G，et al. A systematic review of questionnaires about patient’s values and prefe- rences in clinical practice guidelines[J]. Patient Prefer Adherence，2018，12：2309-2323.

BASTEMEIJER C M，VOOGT L，VAN EWIJK J P，et al. What do patient values and preferences mean? A taxo- nomy based on a systematic review of qualitative papers[J]. Patient Educ Couns，2017，100（5）：871-881.

RONG Y，PATEL V，KIANG T K L. Recent lessons learned from population pharmacokinetic studies of mycophenolic acid：physiological，genomic，and drug interactions leading to the prediction of drug effects[J]. Expert Opin Drug Metab Toxicol，2021，17（12）：1369-1406.

刘爽，张恩瑶，宋再伟，等. 霉酚酸治疗药物监测必要性的系统评价与Meta分析[J]. 中国医院药学杂志，2021，41（5）：495-501，511.

LIU S，ZHANG E Y，SONG Z W，et al. Systematic review and meta-analysis on the necessity of therapeutic drug monitoring of mycophenolic acid[J]. Chin J Hosp Pharm，2021，41（5）：495-501，511.

DOWNING H J，PIRMOHAMED M，BERESFORD M W，et al. Paediatric use of mycophenolate mofetil[J]. Br J Clin Pharmacol，2013，75（1）：45-59.

CAI M Y，ZHOU L，GAO D H，et al. A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019[J]. Front Pharmacol，2023，14：1022134.

YIN T，LIANG H Y，HUANG Q，et al. A survey of therapeutic drug monitoring status in China[J]. Ther Drug Monit，2023，45（2）：151-158.

刘爽，张恩瑶，易湛苗，等. 中国霉酚酸治疗药物监测的现状分析[J]. 中国临床药理学杂志，2021，37（3）：308-311.

LIU S，ZHANG E Y，YI Z M，et al. Analysis for the current status of mycophenolic acid therapeutic drug monito- ring in China[J]. Chin J Clin Pharmacol，2021，37（3）：308-311.

ZENG L N，YI Q S，HUANG L，et al. The guideline for therapeutic drug monitoring guidelines development[J]. J Evid Based Med，2022，15（3）：272-283.

SERRANO-AGUILAR P，TRUJILLO-MARTIN M D E L M，PÉREZ DE LA ROSA A，et al. Patient participation in a clinical guideline development for systemic lupus erythematosus[J]. Patient Educ Couns，2015，98（9）：1156-1163.

YE Z K，REINTAM BLASER A，LYTVYN L，et al. Gastrointestinal bleeding prophylaxis for critically ill patients：a clinical practice guideline[J]. BMJ，2020，368：16722.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

黔东南州251家基层医疗机构麻醉药品配备与管理现状调查

临床药理学中以问题为基础的教学模式的探索与实践

社区药学服务对高血压患者认知行为的影响的调查分析

基于内分泌科医师问卷调查结果评价武汉市胰岛素类药品集中采购分组办法的合理性及可行性

基于消费者视角的成都市社会药房电子处方及远程药学服务实施现状和效果的调查分析